乳腺癌是女性最常见的癌症。采用内分泌疗法联合细胞周期蛋白4/6依赖性激酶治疗的激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌的无进展生存期约为25个月。该病例代表转移性乳腺癌经过内分泌治疗，可实现长期生存。 一名 40 岁的叙利亚妇女被诊断患有激素受体阴性乳腺癌，接受手术治疗并辅助化疗和放疗。她出现激素受体阳性的局部和淋巴结复发，随后恶性胸腔积液复发。她最初接受化疗，然后接受内分泌治疗，从2014年至今获得完全缓解。该患者还出现了药物不良事件，如心力衰竭和骨质疏松症，但得到了适当的治疗。该病例显示出对转移性乳腺癌伴恶性胸腔积液的持久完全缓解。这表明内分泌治疗在复发性激素受体阳性乳腺癌中的有效性，特别是在无法负担靶向治疗或基因检测的国家。它还强调了更好地理解预后和预测因素的必要性。© 2024。作者。

Breast cancer is the most common cancer in women. Progression-free survival for hormone receptor-positive/human epidermal growth factor receptor-2-negative metastatic breast cancer treated with endocrine therapy in combination with cyclin4/6-dependent kinase is approximately 25 months. This case represents metastatic breast cancer treated with endocrine therapy, leading to long-term survival.A 40-year-old Syrian woman diagnosed with hormone receptor-negative breast cancer was treated surgically with adjuvant chemotherapy and radiotherapy. She developed local and nodal recurrences that were hormone receptor-positive, followed by a recurrence of malignant pleural effusion. She was initially treated with chemotherapy and then placed on endocrine therapy with a complete response from 2014 until now. The patient also suffered from adverse events of medications, such as heart failure and osteoporosis, which were treated appropriately.This case demonstrates a long-lasting complete response to metastatic breast cancer with malignant pleural effusion. This shows the validity of endocrine therapy in recurrent hormone receptor-positive breast cancer, especially in countries that cannot afford targeted therapies or genetic tests. It also highlights the necessity for a better understanding of the prognostic and predictive factors.© 2024. The Author(s).